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Glutamine tract expansion triggers nine neurodegen-
erative diseases by conferring toxic properties to the
mutant protein. In SCA1, phosphorylation of ATXN1
at Ser776 is thought to be key for pathogenesis.
Here, we show that replacing Ser776with a phospho-
mimicking Asp converted ATXN1 with a wild-type
glutamine tract into a pathogenic protein. ATXN1
[30Q]-D776-induced disease in Purkinje cells shared
most features with disease caused by ATXN1[82Q]
having an expanded polyglutamine tract. However,
in contrast to disease induced by ATXN1[82Q] that
progresses to cell death, ATXN1[30Q]-D776 failed
to induce cell death. These results support a model
where pathogenesis involves changes in regions of
the protein in addition to the polyglutamine tract.
Moreover, disease initiation and progression to
neuronal dysfunction are distinct from induction of
cell death. Ser776 is critical for the pathway to neu-
ronal dysfunction, while an expanded polyglutamine
tract is essential for neuronal death.
INTRODUCTION
Spinocerebellar ataxia type 1 (SCA1), typically a late-onset fatal
autosomal dominant neurodegenerative disease, is character-
ized by loss of motor coordination and balance. A prominent
feature of SCA1 pathology is atrophy and loss of Purkinje cells
(PCs) from the cerebellar cortex (Schut, 1950). Besides SCA1
the polyglutamine disorders include spinobulbar muscular
atrophy, Huntington’s disease (HD), dentatorubral-pallidoluysian
atrophy, and SCAs 2, 3, 6, 7, and 17 (Orr and Zoghbi, 2007).
A leading model of pathogenesis holds that the expanded poly-
glutamine tract alone triggers disease through an aggregation-based mechanism (Bates, 2003; Ross et al., 2003). Various
data from studies on HD exemplify this concept; for example,
the presence of inclusions containing mutant huntingtin
N-terminal fragments including the polyglutamine stretch that
correlates with disease in patients and animal models (DiFiglia
et al., 1997; Gutekunst et al., 1999; Kim et al., 2001; Gray
et al., 2008). Such findings support the idea that proteolysis
and the generation of a polyglutamine fragment underlies the
pathogenesis of HD as well as other polyglutamine disorders
(Ross et al., 2003; Graham et al., 2006). However, several reports
show that expansion of a glutamine tract is insufficient to cause
disease (Klement et al., 1998; Katsuno et al., 2002; Emamian
et al., 2003; Tsuda et al., 2005; Graham et al., 2006; Gu et al.,
2009).
Recently we found that ATXN1 interacts with the RNA-binding
motif protein 17 (RBM17) in a Ser776 and polyglutamine length-
dependent fashion (Lim et al., 2008). Intriguingly, replacing Ser
with an Asp at residue 776 increased the interaction of wild-
type ATXN1[30Q] with RBM17 to a level comparable to that
seen with ATXN1[82Q]-S776. Thus, by this biochemical param-
eter, D776 in wild-type ATXN1 generated a protein with
a biochemical property of mutant ATXN1[82Q]. This raises an
interesting question, what is the effect of D776 on the ability of
ATXN1 to cause neurodegeneration in vivo?RESULTS
To examine the biological relevance of D776 in ATXN1 in
a mammalian model of SCA1, we generated transgenic mice
expressing either ATXN1[30Q]-D776 or ATXN1[82Q]-D776 in
cerebellar PCs (see Figures S1A and S1B available online),
a major cellular site of pathology in SCA1. Since disease severity
varies with levels of ATXN1 expression (Burright et al., 1995),
quantitative RT-PCR and western blots were used to assess
SCA1 transgene expression in the cerebellum (Figures S1C
and S1D). The ATXN1[82Q]-D776 line with the highest level of
transgene expression, line 5, was selected for detailed analysis.Neuron 67, 929–935, September 23, 2010 ª2010 Elsevier Inc. 929
Figure 1. Atrophy of Purkinje Cell Dendrites in
ATXN1[30Q]-D776 Mice
Calbindin immunofluorescent confocal images taken at
603 with 1503 enlargements (inserts) from the region of
the molecular layer indicated by the white box.
(A) Purkinje cell dendritic tree of 12-week-old WT/FVB
mice having a molecular layer thickness of 184 mm,
±2.6 SEM (n = 6).
(B) Purkinje cell dendritic tree of 12-week-old ATXN1
[30Q]-S776 homozygous mice having a molecular layer
thickness of 162 mm, ±3.5 SEM (n = 6).
(C) Purkinje cell dendritic tree of 12-week-old ATXN1
[82Q]-S776 mice having a molecular layer thickness of
157 mm, ±2.7 SEM (n = 5).
(D) Purkinje cell dendritic tree of 12-week-old ATXN1
[30Q]-D776 mice having a molecular layer thickness of
159 mm, ±2.4 SEM (n = 4).
See also Figure S1.
Neuron
Disease in Mice Expressing Wild-Type Ataxin-1This line expressed ATXN1mRNA at 50% of that seen in ATXN1
[82Q]-S776 line B05. ATXN1[30Q]-D776 line 2, selected for
study, expressed SCA1 levels comparable to ATXN1[82Q]-
S776 line B05 and twice the level seen in hemizygous ATXN1
[30Q]-S776 line A02. Thus, homozygous ATXN1[30Q]-S776
mice were used as controls for ATXN1[30Q]-D776mice. Figures
S1D andS1E shows that transgenic protein expression inATXN1
[30Q]-D776 and ATXN1[30Q]-S776 homozygous mice is consis-
tent with RNA expression levels withATXN1[30Q]-S776 homozy-
gous mice expressing slightly more than ATXN1[30Q]-D776 and
ATXN1[30Q]-S776 homozygous mice expressing slightly more
ATXN1 than ATXN1[30Q]-D776.
We first examined whether ATXN1[30Q]-D776 induced
pathology in vivo by calbindin immunostaining. In the cere-
bellum, calbindin is specifically expressed throughout PCs
(Nakagawa et al., 1998). PCs from 12-week-old ATXN1[30Q]-
D776 mice showed considerable dendritic atrophy compared
to age-matched homozygous control ATXN1[30Q]-S776 mice
(Figure 1). While themolecular layer was reduced in overall thick-
ness to a similar degree in all of the SCA1 mice, atrophy of the
finer dendritic branches was noticeably more extensive in
ATXN1[82Q]-S776 and ATXN1[30Q]-D776 mice. Figure 1A
shows the dense deposition of PC dendrites in the molecular
layer of a WT/FVB cerebellum. In the molecular layer of ATXN1
[30Q]-S776 homozygous mice there was evidence of some PC
dendritic atrophy, notably some pruning of the finer dendritic
branches (Figure 1B). In ATXN1[82Q]-S776 and ATXN1[30Q]-
D776 mice, pruning of PC dendrites was even more extensive
(Figures 1C and 1D, respectively), with the PC dendritic atrophy930 Neuron 67, 929–935, September 23, 2010 ª2010 Elsevier Inc.in ATXN1[30Q]-D776mice similar to that seen in
ATXN1[82Q]-S776 mice.
As a further pathological assessment, we
examined placement of excitatory synaptic
terminals onto PCs in SCA1 mice. The two
major excitatory projections to PCs, parallel
fibers (PFs) and climbing fibers (CFs), segregate
the sites of their terminals (Ito, 1984). While PF-
PC synapses localize to the distal portions of
the PC dendritic arbor, CF-PC synapses areconfined to the apical dendrite and the proximal portion of the
dendritic tree. Each presynaptic terminal can be defined by the
expression of vesicular glutamate transporters (VGLUTs). PF
terminals express VGLUT1 while CF terminals express VGLUT2
(Fremeau et al., 2001). No detectable difference in the immuno-
staining pattern for VGLUT1 in cerebellar sections fromWT/FVB,
ATXN1[82Q]-S776, and ATXN1[30Q]-D776 mice was found
(data not presented). Strong VGLUT1-immunoreactive puncta
representing PF boutons filled the molecular layer of all three
genotypes.
To assess the spatial distribution of CF terminals on PCs in the
SCA1 mice, cerebellar sections were immunostained for
VGLUT2. Figure 2A shows that in 12-week-old WT/FVB mice
the distribution of VGLUT2 staining extended along the primary
and secondary dendrites of PCs to a mean relative height of
0.86 of the molecular layer. In 12-week-old ATXN1[30Q]-S776
homozygous mice (Figure 2B), the mean relative height of CF
terminals along PC dendrites was reduced to 0.81. In age-
matched ATXN1[82Q]-S776 mice the mean relative height
of the CF terminal extension was reduced further to 0.78
(Figure 2C). Interestingly, in 12-week-old ATXN1[30Q]-D776
mice the extension of CF terminals on PC dendrites was consid-
erably more compromised where the CF terminals extended into
the molecular layer to a mean relative height of 0.69 (Figure 2D).
Morphology of CF innervation of PCswas assessed directly by
anterograde labeling of olivocerebellar projections. Injection of
biotinylated dextran-amine into the contralateral inferior olive
was used to visualize individual CFs and their terminals on
PCs. In WT/FVB mice, as the CFs reached the inner portion of
Figure 2. Altered Distribution of Climbing Fiber Terminals on Purkinje Cell Dendrites in 12-Week-Old SCA1 Mice
(A–D) Distribution of CF terminals assessed by VGLUT2 immunostaining. Left panel is calbindin immunofluorescence (green) of Purkinje cells and right panel is
VGLUT2 immunostaining (red) depicting CF terminals. (A) WT/FVB mice showing a mean relative CF to molecular layer thickness height of 0.86 ± 0.006 SEM
(n = 6). (B) ATXN1[30Q]-S776 homozygous mice with a mean relative CF to molecular layer thickness height of 0.81 ± 0.009 SEM (n = 6). (C) ATXN1[82Q]-
S776 mice having a mean relative CF to molecular layer thickness height of 0.78 ± 0.012 SEM (n = 5). (D) ATXN1[30Q]-D776 mice with a mean relative CFs to
molecular layer thickness height of 0.69 ± 0.019 SEM (n = 4).
(E–H) Distribution of CF terminals assessed by anterograde olivocerebellar projection labeling. In each panel, Purkinje cells were identified by calbindin immu-
nofluorescence (red) and climbing fiber tracts by the presence of biotin conjugated to Alexa Fluor 488 (green) following injection into the contralateral inferior olive.
(E) Distribution of CF terminals on Purkinje cells in a 12-week-oldWT/FVBmouse. (F) Distribution of CF terminals on Purkinje cells in a 12-week-old ATXN1[30Q]-
S776 homozygous mouse. (G) Distribution of CF terminals on Purkinje cells in a 12-week-old ATXN1[82Q]-S776 mouse. (H) Distribution of CF terminals on
Purkinje cells in a 12-week-old ATXN1[30Q]-D776 mouse.
See also Figure S1.
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coursed along PC dendrites and extended to positions near
the pial surface (Figure 2E). CFs in ATXN1[30Q]-S776 homozy-
gous mice had a modest level of CF pruning compared to WT/
FVB animals (Figure 2F). Labeled CFs in ATXN1[82Q]-S776
and ATXN1[30Q]-D776 mice failed to branch to an extent seen
in either WT/FVB or in ATXN1[30Q]-S776 homozygous mice
(Figures 2G and 2H, respectively). Thus, anterograde labeling
of inferior olivary neurons supported the conclusion that CF
arborization and extension along PC dendrites was diminished
in ATXN1[82Q]-S776 and ATXN1[30Q]-D776 mice.
The neurological status of ATXN1[30Q]-D776mice was deter-
mined by measuring balance/motor coordination and gait
performance. Figure 3A shows that at 6 and 12 weeks of age,
ATXN1[30Q]-D776 mice were significantly impaired on the
accelerating Rotarod compared to WT/FVB and ATXN1[30Q]-
S776 homozygous mice to a degree similar to that for ATXN1
[82Q]-S776 mice (Figure 3A). Using the DigiGait system, hind
stance width was evaluated since it corresponds to the broad-
based gait typical of SCA1 specifically and ataxia generally in
humans (Manto, 2005). As shown in Figure 3B, at 12 weeks of
age the hind stance width did not significantly differ between
the two control strains (WT/FVB andATXN1[30Q]-S776 homozy-
gousmice). In contrast, age-matchedmice from the two affectedSCA1 lines, ATXN1[82Q]-S776 and ATXN1[30Q]-D776 animals,
had a significantly wider hind stance than age-matched litter-
mate controls (Figure 3B). Thus, by two measures of motor
performance, the ataxia in ATXN1[30Q]-D776 mice was as
severe as the ataxia in ATXN1[82Q]-S776 mice.
A feature of disease in ATXN1[82Q]-S776 mice is that the
neurological deficit progresses with age (Clark et al., 1997). By
30 weeks of age, disease in both ATXN1[82Q]-S776 and
ATXN1[30Q]-D776 mice progressed such that animals of both
genotypes were essentially unable to perform the accelerating
Rotarod task (Figure 3C). Thus, like ATXN1[82Q]-S776 mice
ATXN1[30Q]-D776 mice also have a progressive neurological
disease.
In ATXN1[82Q]-S776 animals, pathology eventually prog-
resses to where PCs die (Clark et al., 1997). To assess ATXN1-
D776-induced disease at a late stage, we examined pathology
in 1-year-old ATXN1[30Q]-D776 and compared it to pathology
in ATXN1[82Q]-S776 animals. The molecular layer in 1-year-old
WT/FVB mice was on average 170 mm thick (Figure S2A).
Year-old ATXN1[82Q]-S776 mice showed severe atrophy of
PCs as quantified by molecular layer thickness as well as
PC loss. The thickness of the molecular layer in these mice
decreased to 123 mm in year-old animals (Figure S2B). In
contrast, PC atrophy in one-year ATXN1[30Q]-D776 mice wasNeuron 67, 929–935, September 23, 2010 ª2010 Elsevier Inc. 931
Figure 3. Altered Neurological Status of ATXN1
[30Q]-D776 Mice
(A) Accelerating Rotarod performance on day 4 at 6 and
12 weeks-of-age. ATXN1[30Q]-S776/S776 (homozygous)
mice, at 6 and 12 weeks (n = 9), were compared to age-
matched WT/FVB mice, at 6 and 12 weeks (n = 10).
ATXN1[30Q]-D776mice at 6 weeks (n = 5) and at 12weeks
(n = 14), compared to age-matched littermate WT/FVB
mice at 6 weeks (n = 9) and at 12 weeks (n = 12; *p =
0.025 and **p = 0.0008, student t test, two tailed equal
variance). Performance of ATXN1[82Q]-S776 mice, at
6 weeks and 12weeks (n = 15), compared to age-matched
littermate WT/FVB mice, at 6 weeks and at 12 weeks
(n = 8; *p = 0.006 and **p = 0.0005, student t test, two tailed
equal variance). ±SEM.
(B) ATXN1[30Q]-D776 mice (n = 9, *p = 0.008 student t
test, two tailed equal variance) show a similar gait perfor-
mance defect as ATXN1[82Q]-S776 mice (n = 20, **p =
0.005 student t test, two tailed equal variance) compared
to age-matched littermate WT/FVB mice (n = 9 &16,
respectively) as assessed by hind stance width at
12 weeks-of-age. ±SEM.
(C) Four day trial of accelerating Rotarod performance of
mice at 30 weeks-of-age. Both ATXN1[30Q]-D776 (n = 3)
mice and ATXN1[82]-S776 (n = 4) at 30 weeks of age
were compared to age-matched WT/FVB (n = 3) (p =
0.04 and p = 0.03). ±SEM.
See also Figure S1.
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ATXN1[30Q]-D776 mice showed little further atrophy from that
seen at 12 weeks of age, decreasing from 159 mm at 12 weeks
(see Figure 1D) to 148 mm at one year (Figure 4A). Thus, even
though ATXN1[30Q]-D776 was able to induce neuronal dysfunc-
tion and initial dendritic atrophy similar to ATXN1[82Q]-S776, in
absence of an expanded polyglutamine tract progression of
dendritic atrophy was reduced considerably and disease failed
to advance to neuronal cell death.
Failure of disease to induce PC death in ATXN1[30Q]-D776
mice could be due to either the absence of an expanded poly-
glutamine tract or the presence of a D776. To address this, we
characterized disease and its progression in animals expressing
ATXN1[82Q]-D776. In these mice, immunostaining with the anti-
ATXN1 antibody 11750 (Servadio et al., 1995) showed that
ATXN1[82Q]-D776 protein was expressed in nuclei of PCs in
a spatial fashion similar to the ATXN1[82Q]-S776 protein in
mice from the B05 line. Consistent with the mRNA expression
analysis (Figure S1C), immunostaining revealed that the expres-
sion level of ATXN1[82Q]-D776 (Figure S2C) was considerably932 Neuron 67, 929–935, September 23, 2010 ª2010 Elsevier Inc.less than ATXN1[82Q]-S776 (Figure S2D). Yet,
as assessed by measuring the thickness of the
molecular layer, ATXN1[82Q]-D776 induced
a similar amount of PC dendritic atrophy as
did ATXN1[82Q]-S776. At 12 weeks of age, the
molecular layer was considerably reduced
from a mean of 184 mm in age-matched wild-
type mice to 147 mm in ATXN1[82Q]-D776
mice and to 157 mm in ATXN1[82Q]-S776
animals (Figures 4B and 4C). Neurologicalassessment by the accelerating Rotarod indicated that ATXN1
[82Q]-D776 mice were severely affected by 12 weeks of age
(Figure 4D). Thus, it took less ATXN1[82Q]-D776 than ATXN1
[82Q]-S776 to induce a similar level of disease, indicating that
D776 enhanced the pathogenicity of ATXN1[82Q]. Importantly,
progression of Purkinje cell atrophy was more severe in year-
old ATXN1[82Q]-D776 cerebella. The molecular layer of year-
old ATXN1[82Q]-D776 mice was on average 97 mm (Figure 4E),
considerably less than 123 mm in year-old ATXN1[82Q]-S776
cerebella (Figure S2B). Clearly, a D776 did not prevent induction
of cell death and, if anything, enhanced pathology with age given
that these mice expressed less ATXN1 than ATXN1[82Q]-S776
animals.
DISCUSSION
Here, we show that a single amino acid substitution outside of
the polyglutamine tract converted wild-type ATXN1 into a
protein, which in a mammalian model of SCA1 has many of
the pathogenic capabilities of the protein with an expanded
Figure 4. Cerebellar Pathology in Year-Old SCA1
Mice
(A) Calbindin immunofluorescence of Purkinje cells in one-
year-old mice expressing ATXN1[30Q]-D776 showing
a molecular layer thickness of 148 ± 3.8 mm SEM (n = 3).
Insert shows the absence of nuclear inclusions in PC
nuclei assessed by triple immunostaining for ATXN1
(green), ubiquitin (red), and calbindin (blue). Image is
a single z scan (1803).
(B) Calbindin (red) and ATXN1 (green) immunofluores-
cence in Purkinje cells of 12-week-old mice expressing
ATXN1[82Q]-D776. Average molecular thickness was
147 ± 2.1 mm SEM (n = 3).
(C) Calbindin (red) and ATXN1 (green) immunofluores-
cence in Purkinje cells of 12-week-old mice expressing
ATXN1[82Q]-S776. Average molecular thickness was
157 ± 2.8 mm SEM (n = 5).
(D) Accelerating Rotarod performance on day 4 of 6
(n = 12) and 12-week-old ATXN1[82Q]-D776 (n = 5)
compared to WT/FVB littermate controls, (n = 12 and 4,
respectively), *p = 0.02, student t test two-tailed equal
variance). ±SEM.
(E) Calbindin immunofluorescence of Purkinje cells in
1-year-old mice expressing ATXN1[82Q]-D776 with
a molecular layer thickness of 97 ± 7.0 mm SEM (n = 3).
Insert depicts the presence of ubiquitin positive nuclear
inclusions in PC nuclei as revealed by triple immunostain-
ing for calbindin (blue), ATXN1 (green), and ubiquitin (red).
Image is a single z scan (1803).
See also Figures S1 and S2.
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outside of the polyglutamine tract influence toxicity of a mutant
polyglutamine protein (Klement et al., 1998; Katsuno et al.,
2002; Emamian et al., 2003; Tsuda et al., 2005; Graham et al.,
2006; Gu et al., 2009). This study demonstrates that a D776
substitution enhanced pathogenicity of ATXN1[82Q], revealing
that an expanded polyglutamine tract and S776 phosphorylation
have a synergistic effect on toxicity. Moreover, a D776 converted
ATXN1[30Q] into a highly pathogenic protein. Thus, placing anNeuron 67, 929–9Asp at position 776 in ATXN1 mimics patho-
genic affects of polyglutamine expansion,
strongly supporting a model where polyglut-
amine expansion has its pathogenic effect
largely by altering a property associated with
another region of the protein. In particular,
we argue that D776 promotes the formation
of ATXN1-RBM17-containing complexes that
underlie some of the toxic gain of functions
(Lim et al., 2008). Consistent with this idea is
the observation of an increase in the amount
of RBM17 in high molecular weight complexes
in both ATXN1[82Q]-S776 and ATXN1[30Q]-
D776 mice (Figure S3).
ALS nicely illustrates the concept of initiation
and progression as being distinct stages of
neurodegenerative disease, where evidence
indicates that mutant SOD1 damage within
motor neurons is linked to initiation and early
stages of progression (Boille´e et al., 2006).A mechanistically divergent later phase encompassing the
progression to complete paralysis is coupled to the inflammatory
response of microglia and mutant SOD1 toxicity within these
cells (Boille´e et al., 2006; Beers et al., 2006). Thus, in SOD1-
induced ALS the distinct phases of disease are due to the
actions of mutant protein in different cell types to produce
a non-cell-autonomous killing of motor neurons. In the case of
SCA1, we show that within one neuronal cell type, disease initi-
ation and progression to neurological dysfunction can also be35, September 23, 2010 ª2010 Elsevier Inc. 933
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Disease in Mice Expressing Wild-Type Ataxin-1distinct from later phases of disease. ATXN1[30Q]-D776 induced
disease initiation and PC dysfunction. However, only in mice
expressing ATXN1 with an expanded polyglutamine tract was
the late-stage feature PC death seen. These results illustrate
that PC death is not the cause of the neurological phenotype in
SCA1 mice. The ATXN1[30Q]-D776 mice become as neurologi-
cally compromised as ATXN1[82Q]mice without induction of PC
death. It is worth noting that ATXN1[30Q]-D776-expressing PCs
showed no sign of ATXN1 nuclear inclusions out to 1 year of age
(Figure 4A). This is in contrast to ATXN1[82Q]-D776 mice that
showed PC nuclear inclusions similar to ATXN1[82Q]-S776
animals (Figures 4E and S2B, respectively), suggesting that
inclusion formation and induction of cell death require the poly-
glutamine expansion.
Two hypotheses for pathogenicity in the polyglutamine disor-
ders involve (1) the generation of a toxic polyglutamine fragment
(Ross et al., 2003) and (2) a toxic role of the expanded CAG
repeat containing RNA (Li et al., 2008). The finding in the
ATXN1[30Q]-D776 mice that a protein is pathogenic in absence
of an expanded polyglutamine tract argues against either
proteolytic cleavage and the generation of a toxic polyglut-
amine-containing fragment or an RNA with an expanded CAG
repeat as general mechanisms for polyglutamine pathogenesis.
We suggest that pathogenesis can involve changes in regions of
the protein in addition to the polyglutamine tract. In the case
of SCA1 and ATXN1, placing an Asp at residue 776 mimics
one such change.
Our finding that a phosphomimetic D776 promotes disease,
combined with previous data showing that S776 is an endoge-
nous site of phosphorylation and a phosphoresistant A776
prevents development of ataxia (Emamian et al., 2003), support
the concept that S776 phosphorylation in ATXN1 drives disease
initiation and development of neuronal dysfunction. Finding an
inhibitor of S776 phosphorylation that suppresses disease will
test this model directly as well as provide an important step
toward a treatment for SCA1. It is worth noting that pathogenesis
correlates with disease protein phosphorylation in other neuro-
degenerative diseases, e.g., a-synuclein (Fujiwara et al., 2002),
and tau (Ballatore et al., 2007). More recently, substitution of
phosphomimetic Asp for a Ser at residues 13 and 16 of mutant
huntingtin abolished the ability of the protein to induce disease
in vivo (Gu et al., 2009). Thus, targeting phosphorylation for
therapeutic developmentmay be applicable tomultiple neurode-
generative diseases.
Lastly, it is worth emphasizing that beyond showing that one
amino acid change can make a wild-type protein toxic we
show that disease initiation and late-stage induction of neuron
death are distinct phases. Obviously, the two are linked in that
initiation is a prerequisite of later stages. Thus, a treatment
targeted at initiation, perhaps S776 phosphorylation, is likely to
have a major impact.EXPERIMENTAL PROCEDURES
Transgenic Mice
The Institutional Animal Care and Use Committee approved all animal use
protocols. Mice were housed and managed by Research Animal Resources
under SPF conditions in an AAALAC-approved facility. ATXN1[30Q]-S776934 Neuron 67, 929–935, September 23, 2010 ª2010 Elsevier Inc.mice were from the A02 line and ATXN1[82Q]-S776 mice from line B05
(Burright et al., 1995). The ATXN1[30Q]-D776 and ATXN1[82Q]-D776 trans-
genes were generated by adding a point mutation in the original construct
used to make the ATXN1[30Q]-S776 mice. These transgenes were linearized
with BamHI, gel isolated, purified by phenol/chloroform extraction, chloroform
extraction, and ethanol precipitation, and suspended in injection buffer
(10 mM Tris-Cl [pH 8.0]; 0.1 mM EDTA) at a concentration of 4 ng/ml. Embryo
injections were performed by the Mouse Genetics Laboratory, University of
Minnesota. PCR and Southern blot analyses were used to identify transgene
positive animals. For ATXN1[82Q]-D776, eight lines were generated with five
expressing the transgene all of which developed signs of disease. In the
case of ATXN1[30Q]-D776, six lines were obtained with three expressing the
transgene.
Immunostaining and Quantitative Measurements
Animals were perfused with 10% formalin and 50 mm sections were cut on
a vibratome as previously described (Zu et al., 2004). Epitopes were unmasked
by boiling three times for 15 s each in 0.01 M urea. The sections were blocked
for 1 hr in 2% normal donkey serum and 0.3% Triton X-100 in 13 PBS. After
blocking, the sections were incubated for 48 hr at 4C in blocking solution
containing primary antibody, rabbit ATXN1 11750 or 12NQ antibody at
1:2000 (Servadio et al., 1995), goat calbindin antibody (SC-7691, Santa
Cruz) at 1:500, rabbit VGLUT1 antibody (135–302, Synaptic Systems) at
1:2000, or mouse VGLUT2 antibody (MAB5504, Millipore) at 1:1000 or mouse
ubiquitin at 1:250 (13–1600, Invitrogen). The sections were washed 4 times in
PBS and incubated for 48 hr in blocking solution containing secondary
antibody. Donkey secondary Cy2, Cy3, and Cy5 were used at 1:500 (Jackson
Immunoresearch). Sections were washed and mounted onto microscope
slides with glycerol-gelatin (Sigma) containing 4 mg/ml n-propyl gallate. Fluo-
rescent images were scanned using an Olympus Fluoview 1000 IX2 inverted
microscope as previously described (Klement et al., 1998).
To assess the height theCF extends along the PCdendrite and the thickness
of the molecular layer, 203 images were measured using Fluoview Viewer 1.7
software. Measurements of molecular layer thickness were taken on calbindin
immunostained sections by measuring the distance from the base of the PC
body to the end of the dendrite at the pial surface. Six measurements at the
primary fissure from three cerebellar sections per animal were averaged.
VGLUT2 staining was used to determine CF terminal deposition. A minimum
of three animals was measured for each time point. The extension of CF
terminals was depicted relative to the molecular layer thickness. Data are
expressed as the mean ± SEM. The p value was calculated using Student’s
t test (two-tailed equal variance).
Climbing Fiber Tract Analysis—Anterograde Labeling
Animals were anesthetized with a ketamine/xylazine cocktail (100 mg ket-
amine and 10 mg xylazine per kg body WT) by intramuscular injection and
placed into a stereotaxic frame (Model 963LS, David Kopf Instruments). The
dorsal surface of the brainstem was exposed and a glass micropipette was
inserted into the inferior olive. Three hundred nanoliters of 5% dextran conju-
gated to Alexa Fluor 488 (10,000 MW, Molecular Probes, Eugene, OR) in water
was bilaterally injected using a microinjector (Model 5000, David Kopf Instru-
ments). Five to seven days later, mice were transcardially exsanguinated with
PBS (pH 7.4) and perfused with 10% formalin (25 ml). Brains were removed
and fixed overnight in 10% formalin at room temperature, and placed in
30% sucrose in PBS overnight at 4C. Cerebella were sectioned (50 mm) using
a freezing sliding microtome. Purkinje cells were immunostained with anti-cal-
bindin as described above, mounted on gelatin-coated slides, and examined
using a fluorescent microscope.
Motor Performance Analyses
Accelerating Rotarod analysis was performed on 12-week-old FVB and
ATXN1[30Q]-D776 mice as described (Clark et al., 1997). Gait performance,
as assessed by hind stance width, was determined using DigiGait (Mouse
Specifics inc., Boston MA, USA) as described (Pallier et al., 2009). Twelve-
week-old transgenic and wild-type littermates were run at 35 cm/s. The
DigiGait system consists of Plexiglas housing over a clear treadmill belt.
A video camera captures mice walking and 5–6 s are used for analysis.
Neuron
Disease in Mice Expressing Wild-Type Ataxin-1Analysis software plots the individual paws as they contact the treadmill and
calculates gait parameters. A student t test was used to show statistical
significance.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.neuron.2010.08.022.
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